Cargando…

Comparative Assessment of the Magnitude of Hyperlipidemia in HIV-Infected Patients Receiving Lopinavir/r- and Atazanavir/r-Based Antiretroviral Drugs

OBJECTIVE: To assess prevalence of hyperlipidemia in patients receiving lopinavir boosted with ritonavir (LPV/r) and atazanavir boosted with ritonavir (ATV/r) antiretroviral drugs. METHODS: HIV-infected patients (300) were recruited in the study between December 2015 and April 2016. Lipid profile in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muya, Esther, Kamuhabwa, Appolinary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748546/ https://www.ncbi.nlm.nih.gov/pubmed/30995874 http://dx.doi.org/10.1177/2325958219841908

Ejemplares similares

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis
por: Tigabu, Bereket Molla, et al.
Publicado: (2020)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Atazanavir versus lopinavir on Covid-19 infection: A retrospective protease inhibitors comparative study 2020
por: Alikhani, Ahmad, et al.
Publicado: (2022)

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
por: Smith, Christiana, et al.
Publicado: (2016)

Outcomes in antiretroviral-naive HIV-infected patients initiating therapy with TDF/FTC plus either atazanavir/r or another third recommended drug
por: Billaud, E, et al.
Publicado: (2010)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
por: Henrivaux, Philippe, et al.
Publicado: (2010)

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
por: LaFleur, Joanne, et al.
Publicado: (2017)

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir
por: Jose, Sophie, et al.
Publicado: (2017)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Adherence, Effectiveness and Safety of Dolutegravir Based Antiretroviral Regimens among HIV Infected Children and Adolescents in Tanzania
por: Mutagonda, Ritah F., et al.
Publicado: (2022)

Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy
por: Vesterbacka, Jan, et al.
Publicado: (2013)

Drug use in pregnancy: Knowledge of drug dispensers and pregnant women in Dar es Salaam, Tanzania
por: Kamuhabwa, Appolinary, et al.
Publicado: (2011)

A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
por: Ulbricht, K.U, et al.
Publicado: (2011)

Two Cases of Multidrug-Resistant Human Immunodeficiency Virus Infection Treated with Atazanavir and Lopinavir/Ritonavir Combination Therapy
por: Choi, Heekyoung, et al.
Publicado: (2008)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Knowledge among drug dispensers and antimalarial drug prescribing practices in public health facilities in Dar es Salaam
por: Kamuhabwa, Appolinary AR, et al.
Publicado: (2013)

Week 120 Efficacy of Tenofovir, Lamivudine and Lopinavir/r-Based Second-Line Antiretroviral Therapy in Treatment-Experienced HIV Patients
por: Han, Yang, et al.
Publicado: (2015)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Challenges facing effective implementation of co-trimoxazole prophylaxis in children born to HIV-infected mothers in the public health facilities
por: Kamuhabwa, Appolinary AR, et al.
Publicado: (2015)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
por: Dubrocq, Gueorgui, et al.
Publicado: (2017)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania
por: Sangeda, Raphael Z, et al.
Publicado: (2018)

Magnitude of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative and Beta-Lactamase-Producing Gram-Positive Pathogens Isolated from Patients in Dar es Salaam, Tanzania: A Cross-Sectional Study
por: Mloka, Doreen, et al.
Publicado: (2022)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
por: Alomar, Fadhel A., et al.
Publicado: (2022)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
por: Foglia, Emanuela, et al.
Publicado: (2013)

Current evidence for the risk of PR prolongation, QRS widening, QT prolongation, from lopinavir, ritonavir, atazanavir, and saquinavir: A systematic review
por: Ridjab, Denio A., et al.
Publicado: (2021)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe
por: Ngara, Bernard, et al.
Publicado: (2021)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Adverse birth outcomes among mothers who received intermittent preventive treatment with Sulphadoxine-Pyrimethamine in the low malaria transmission region
por: Mikomangwa, Wigilya P., et al.
Publicado: (2019)

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy
por: Martin, Allison, et al.
Publicado: (2013)

Implementation of co-trimoxazole preventive therapy policy for malaria in HIV-infected pregnant women in the public health facilities in Tanzania
por: Kamuhabwa, Appolinary AR, et al.
Publicado: (2016)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
por: Foglia, Emanuela, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6mla64gnq2fjuhqg9iriv35mu4